A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera;Une mutation unique de la protéine kinase JAK2 dans la polyglobulie de Vaquez et les syndromes myéloprolifératifs non-LMC

Medecine/Sciences

Volumn 21, Issue 6-7, 2005, Pages 669-670

  Ugo, Valérie ^a   James, Chloé ^b   Vainchenker, William ^b  

^a BREST UNIVERSITY HOSPITAL   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; JANUS KINASE 2;

EOSINOPHILIA; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; MYELOPROLIFERATIVE DISORDER; NOTE; POLYCYTHEMIA VERA; SPLENOMEGALY; THROMBOCYTHEMIA;

EID: 22144452197     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/2005216-7669     Document Type: Note

References (18)

1. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO): classification of myeloid neoplasms. Blood 2002; 100: 2292-302.
2. Wong S, Witte ON. The BCR-ABL story: bench to bedside and back. Annu Rev Immunol 2004; 22: 247-306.
3. Cross NC, Reiter A. Tyrosine kinase fusion genes in chronic myeloproliferative diseases. Leukemia 2002; 16: 1207-12.
4. Gotlib J, Cools J, Malone JM, et al. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia implications for diagnosis, classification and management. Blood 2004; 103: 2879-91.
5. Pardanani A, Tefferi A. Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. Blood 2004; 104: 1931-9.
6. Wadleigh M, De Angela DJ, Griffin JD, Stone RM. After chronic myelogenous leukemia: tyrosine kinase inhibitors in others malignancies. Blood 2005; 105: 22-30.
7. Pahl HL. Towards a molecular understanding of polycythemia rubra vera. Eur J Biochem 2000; 267: 3395-401.
8. Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood 2002; 100: 4272-90.
9. Ugo V, Marzac C, Teyssandier I, et al. Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Exp Hematol 2004; 32: 179-87.
10. James C, Ugo V, Le Couedic JP, et at. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-8.
11. Kralovics R, Guan Y, Prchal JT. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol 2002; 30: 229-36.
12. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-61.
13. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-90.
14. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-97.
15. Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in Polycythemia vera. J Biol Chem 2005 online.
16. Goldman JM. A unifying mutation in chronic myeloproliferative disorders. N Engl Med 2005; 352: 1744-6.
17. Kaushansky K. On the molecular origins of the chronic myeloproliferative disorders: it all makes sense. Blood 2005; 105: 4187-90.
18. Shannon K, Van Etten RA. JAKing up hematopoietic proliferation. Cancer Cell 2005; 7: 291-3.